Possible Bearish Signals With Rocket Pharmaceuticals Insiders Disposing Stock
Possible Bearish Signals With Rocket Pharmaceuticals Insiders Disposing Stock
The fact that multiple Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)多位内部人士在过去一年大量卖出股票的事实可能引起了投资者的关注。在评估内部交易时,了解内部人士是否在买入股票通常更有帮助,因为内部人士卖出股票可能有多种解释。但是,当多个内部人士在特定时间段内出售股票时,股东应该注意到,因为这可能是一个红旗信号。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
虽然我们绝不建议投资者仅基于公司董事所做的事情来作出决策,但我们认为密切关注内部人士所做的事情是完全合理的。
The Last 12 Months Of Insider Transactions At Rocket Pharmaceuticals
Rocket Pharmaceuticals上市以来内部交易情况总结
The CEO & Director, Gaurav Shah, made the biggest insider sale in the last 12 months. That single transaction was for US$605k worth of shares at a price of US$29.84 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$19.04. So it is hard to draw any strong conclusion from it.
董事兼CEO Gaurav Shah在过去12个月中进行了最大额的内部交易。那笔单独的交易是以每股29.84美元的价格购买了60.5万美元的股票。通常情况下,我们不喜欢看到内部人士卖出股票,但如果销售价格较低,则更加令人担忧。好消息是,这次大规模售卖的价格高于现价19.04美元。因此,很难从中得出任何强烈的结论。
Rocket Pharmaceuticals insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
Rocket Pharmaceuticals内部人士在过去一年内没有购买任何股份。你可以看到下面过去12个月内内部交易(包括公司和个人)的可视化描述。通过点击下面的图表,您可以查看每个内部交易的详细信息!
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240811/0-4490a26574815766956777939f72ce70-0-7179f111e16f6892f58b74e3af346758.png/big)
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜欢购买内部人员正在购买而不是销售的股票,那么你可能会喜欢这份免费的公司列表。(提示:它们中的大部分都被忽视了。)
Rocket Pharmaceuticals Insiders Are Selling The Stock
Rocket Pharmaceuticals内部人士正在抛售该股票
The last three months saw significant insider selling at Rocket Pharmaceuticals. Specifically, insiders ditched US$453k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
过去三个月,Rocket Pharmaceuticals的内部人士大量抛售了股票。具体来说,内部人士在这段时间内抛售了45.3万美元的股票,而我们没有记录任何购买记录。这可能意味着一些内部人士认为股票不便宜。
Does Rocket Pharmaceuticals Boast High Insider Ownership?
Rocket Pharmaceuticals内部人士持股高吗?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Rocket Pharmaceuticals insiders own about US$44m worth of shares. That equates to 2.5% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
测试公司领导人与其他股东之间的关系的另一种方法是查看他们拥有的股数。我们通常希望看到相当高水平的内部人士持股比例。Rocket Pharmaceuticals的内部人员拥有约4400万美元的股份,相当于该公司的2.5%。我们当然看到其他地方持股比例更高,但这些持股足以表明内部人士与其他股东之间的关系良好。
So What Does This Data Suggest About Rocket Pharmaceuticals Insiders?
那么,这些数据对Rocket Pharmaceuticals的内部人士意味着什么呢?
Insiders sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 4 warning signs for Rocket Pharmaceuticals you should be aware of, and 1 of these is significant.
内部人士最近抛售了股票,但他们没有购买。过去一年中也没有任何购买记录,这让我们对该公司持谨慎态度。内部人士持股比例并不特别高,因此这份分析让我们对该公司保持谨慎。因此,在仔细考虑后才会购买。因此,这些内部交易可以帮助我们建立有关该股票的论点,但是知道这家公司面临的风险也很值得。例如:我们发现了Rocket Pharmaceuticals 4个警告信号,您应该注意其中1个是重要警告信号。
But note: Rocket Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
请注意:Rocket Pharmaceuticals可能不是最好的股票购买选择。因此,请查看具有高roe和低负债的有趣公司的免费列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。